Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, posted on X:
“Just published!
Our review on HER2-altered NSCLC – from biology and testing to latest therapies.
Biomarker testing: tissue and ctDNA
ADCs and TKIs: T-DXd, zongertinib, A166, ARX788
Future: combo trials and next-gen agents.”
Ahmed Ismail, Former Research Fellow at the UAB O’Neal Comprehensive Cancer Center, shared a post by Aakash Desai on X, adding:
“I am so happy to see our review published in Frontiers in Oncology with my amazing mentors at the UAB O’Neal Comprehensive Cancer Center”
Title: HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities
Journal: Frontiers in Oncology
Authors: Ahmed Ismail, Desai Aakash, Yanis BoumberAhmed Ismail, Desai Aakash, Yanis Boumber
More posts featuring Aakash Desai on OncoDaily.
